1. Fig. 1 Comparison of LOX concentrations between study groups
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), kez035,
The content of this slide may be subject to copyright: please see the slide notes for details.

2. Comparison of LOX concentrations between SSc patients with sPAP > and ...
Comparison of LOX concentrations between SSc patients with sPAP > and <40 mmHg.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), kez035,
The content of this slide may be subject to copyright: please see the slide notes for details.

3. (a) Correlation between LOX concentration and Medsger disease severity scale in SSc ...
(a) Correlation between LOX concentration and Medsger disease severity scale in SSc patients. (b) Correlation between LOX concentration and DLCO.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), kez035,
The content of this slide may be subject to copyright: please see the slide notes for details.

4. (a) Haematoxylin and eosin staining (×100) and LOX immunostaining of a skin biopsy ...
(a) Haematoxylin and eosin staining (×100) and LOX immunostaining of a skin biopsy from a healthy control showing robust staining in the epidermis (arrow) and some staining near blood vessels in the dermis (arrow head). (b) Haematoxylin and eosin staining (×100) and LOX immunostaining of a skin biopsy from a patient with diffuse SSc showing localization of LOX to fibroblasts mainly in the epidermis (arrow) and near blood vessels in the dermis (arrow head).
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), kez035,
The content of this slide may be subject to copyright: please see the slide notes for details.

5. (a) Haematoxylin and eosin staining (×100) and LOX immunostaining of a lung ...
(a) Haematoxylin and eosin staining (×100) and LOX immunostaining of a lung control biopsy showing scarce staining in the lung parenchyma. (b) Haematoxylin and eosin staining (×100) and LOX immunostaining of a lung biopsy of an SSc patient with PH showing intense staining in the parenchyma and around the blood vessels. (c) Haematoxylin and eosin staining (×100) and LOX immunostaining of a lung biopsy from an SSc patient with pulmonary fibrosis showing diffuse intense staining in the parenchyma and around the blood vessels. (d) Representative images of LOX (red) and α-SMA (green) in lung tissue, demonstrating stronger LOX immunostaining in SSc-associated PH compared with iPAH and control patients. LOX staining is predominantly localized within proliferating endothelium in the walls of remodelled pulmonary vessels. Scale bar = 50 µm in all sections.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
Rheumatology (Oxford), kez035,
The content of this slide may be subject to copyright: please see the slide notes for details.